Allogeneic Stem Cell Transplantation for Aplastic Anemia  by Armand, Philippe & Antin, Joseph H.
A
A
I
n
n
h
n
g
v
v
t
a
i
m
m
u
d
d
a
r
o
b
c
t
d
Biology of Blood and Marrow Transplantation 13:505-516 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1305-0001$32.00/0
doi:10.1016/j.bbmt.2007.02.005llogeneic Stem Cell Transplantation for
plastic Anemia
Philippe Armand, Joseph H. Antin
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Correspondence and reprint requests: Philippe Armand, MD, PhD, Dana-Farber Cancer Institute, 44 Binney
Street, Boston MA 02115 (e-mail: parmand@partners.org).
Received January 31, 2007; accepted February 12, 2007
ABSTRACT
Aplastic anemia encompasses a heterogeneous group of diseases with distinct pathophysiologies and a common
clinical endpoint of marrow failure. Patients with severe aplastic anemia can be treated with immunosuppres-
sive therapy (IST) or hematopoietic stem cell transplantation (HSCT). Over the last 30 years, advances in both
treatment modalities have significantly improved the prognosis for this disease; yet this evolution complicates
the central therapeutic question in aplastic anemia: which patients should receive IST and which ones should
receive HSCT as front-line therapy? In this review, we describe the major improvements that have occurred
in transplantation for aplastic anemia in the last 3 decades. We then outline a framework for deciding which
patients should be considered for upfront transplantation.
© 2007 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Aplastic anemia (AA) was ﬁrst described in a preg-
ant woman by Paul Ehrlich in 1888 [1]. The term
ow refers to a clinical syndrome of bone marrow
ypocellularity accompanied by peripheral pancytope-
ia. Despite this apparent simplicity, AA is a hetero-
eneous disease, and is perhaps more appropriately
iewed as the common pathologic end point of a
ariety of possible injuries to the hematopoietic sys-
em. Disorders leading to aplasia can be inherited or
cquired, with distinct pathophysiologies. The inher-
ted marrow failure syndromes include Fanconi ane-
ia, dyskeratosis congenita, Diamond-Blackfan ane-
ia, and Schwachman-Diamond syndrome. Our
nderstanding of the molecular basis for those disor-
ers has progressed greatly in recent years. The un-
erlying defects have now been mapped to DNA dam-
ge repair mechanisms, telomerase regulation, and
ibosomal function [2]. In contrast, the proximal cause
f acquired aplastic anemia appears in most cases to
e not an intrinsic defect in the hematopoietic stem
ell, but an immune attack on the hematopoietic sys-
em [3]. In some cases, the aplasia can be traced to a
eﬁnite trigger such as a drug or toxin exposure ptwo notorious examples are benzene and chloram-
henicol), seronegative viral hepatitis, or associated
ith other conditions such as paroxysmal nocturnal
emoglobinuria (PNH), pregnancy, or eosinophilic
asciitis [4]. A large epidemiologic study from Thai-
and has also implicated exposure to pesticides and
nimal fertilizer [5]. In the majority of cases, however,
o trigger can be identiﬁed for acquired AA. More-
ver, even when the trigger is known, the mechanism
eading from the causative agent to aplasia is unclear,
lthough the end result is either stem cell loss (often
rreversible) or immune-mediated stem cell destruc-
ion (which may be reversible by immunosuppression
r withdrawal of the offending agent).
For patients with AA requiring treatment, 2 ther-
peutic modalities can be used: immunosuppressive
herapy (IST) or allogeneic hematopoietic stem cell
ransplantation (HSCT). Those modalities have a dif-
erent mechanism of action and very different toxicity
nd efﬁcacy proﬁles (summarized in Table 1), which
ust be taken into account when approaching treat-
ent decisions for a patient who is potentially eli-
ible for both. In this review, we summarize the
ajor advances in the practice of stem cell trans-
lantation for AA, and use this as a basis for
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P. Armand and J. H. Antin506iscussing the choice of ﬁrst-line therapy for patients
ith severe AA. Several excellent reviews have been
reviously written on the topic [3,6-9]. For reference,
esults of selected studies of transplantation and im-
unosuppressive therapy are summarized in Tables 2
nd 3, respectively.
DVANCES IN ALLOGENEIC TRANSPLANTATION
irst Attempts
The ﬁrst (unsuccessful) reported attempt to intra-
enously infuse allogeneic marrow for a patient with
able 1. A Comparison of the Salient Features of Immunosuppressive
herapy (IST) and Allogeneic Hematopoietic Stem Cell
ransplantation (HSCT)
IST HSCT
atient
exclusions
Severe comorbidities Advanced age
Comorbidities
Donor unavailability
elapse risk 35%-45% 5%-20%*
elapse pattern Anytime Early*
arly toxicity Mild (drug adverse
effects)
Conditioning toxicity
(5%-10%)
Acute GVHD (10%-50%)
ate toxicity PNH (15%-20%)
MDS/AML (10%-20%)
Solid tumors (2%)
Chronic GVHD
(20%-50%)
Solid tumors (2%)
Other†
NH indicates paroxysmal nocturnal hemoglobinuria; MDS, my-
elodysplastic syndrome; AML, acute myelogenous leukemia;
GVHD, graft-versus-host disease.
In the transplant setting, relapse refers to graft failure, which
usually occurs early.
Including growth retardation, cataracts, hypothyroidism, and
infertility.
ee text for references.
able 2. Results of Selected Studies of Stem Cell Transplantation for S
Study N*
Median Age
(Range) Conditioning
ahl et al [27] 81 25 (2-63) Cy  ATG
esnick et al [36] 13 20 (9-55) Cy  Flu  ATG
upta et al [40] 33 16 (4-45) Cy  Alemtuzuma
im et al [103] 113 28 (16-50)
Cy  ATG 
Procarbazine
assweg et al [99]‡ 181 16 (1-55) Varied
eeg et al [31]‡ 62 18 (1-53)¶ Cy  ATG  TBI
acigalupo et al [34]‡ 33 14 (3-37)¶ Cy  ATG  Flu
ojima et al [30]‡ 79 17 (1-46)¶ Varied
VHD indicates graft-versus-host disease; GF, graft failure; Cy, c
total-body irradiation; CSA, cyclosporine; Mtx, methotrexate;
matched unrelated donor; OS, overall survival.
Number of patients.
Twenty-one percent of patients received a T cell-depleted graft.
Published results include some patients transplanted from misma
unrelated patients are included in this table.
Includes mismatched unrelated patients.
Or tacrolimus  Mtx; a few patients received other regimens.A dates back to 1939 [10]; one year later, Morrison
nd Samwick [11] performed a sibling marrow trans-
lant through an intrasternal infusion on a patient in
ew York. The outcome was apparently successful,
lthough the patient may not, in fact, have truly suf-
ered from AA. The ﬁrst successful transplant using a
yngeneic donor was reported in 1961 [12], and the
rst successful matched related donor (MRD) trans-
lant in 1972 [13]. Four years later, a randomized
rospective trial from Seattle showed a survival beneﬁt
f MRD HSCT over standard of care (supportive
ransfusions or androgen treatment) [14], proving the
sefulness of transplantation in this disease.
he Importance of Graft Failure
Graft failure (GF) is a central problem in trans-
lantation for AA, occurring more frequently than in
ther HSCT indications. This likely occurs for two
easons: ﬁrst, most conditioning regimens for AA
re nonmyeloablative. In fact, the observation of
utologous recovery with concomitant cure of the
plasia after attempted transplantation [15] is what
rompted the development of high-dose cyclophos-
hamide without grafting, pioneered by Brodsky and
olleagues [16]. Second, and more importantly, the
ntihematopoietic immune activity in the host can
eject the graft by the same mechanism that it attacked
he recipient’s stem cells in the ﬁrst place. In the initial
xperience with MRD transplants in the 1970s, using
yclophosphamide (Cy) alone for conditioning and
ethotrexate alone for graft-versus-host disease
GVHD) prophylaxis, the incidence of GF with MRD
ransplants was up to 30% [17,18]. As would be pre-
icted on pathophysiologic grounds, intensiﬁcation of
he conditioning regimen or of the posttransplanta-
ion immunosuppression can reduce this risk, but may
plastic Anemia
GVHD
ophylaxis Match GF Survival
A  Mtx MRD 4% 15 y OS  88%
A MRD 0% 5 y OS  84%
A MRD 24% 5 y OS  81%
A  Mtx† MRD 15% 6 y OS  89%
ried MUD (serologic typing) 17% 5 y OS  39%
A  Mtx MUD (molecular typing) 1% 5 y OS  61%
A  Mtx MUD (molecular typing) 18% 6 y OS  73%¶
A  Mtx§ MUD (molecular typing) 8% 5 y OS  60%
osphamide; ATG, antithymocyte globulin; Flu, ﬂudarabine; TBI,
, mycophenolate mofetil; MRD, matched related donor; MUD,
donors; except where indicated, only the results for the matchedevere A
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Allogeneic Stem Cell Transplantation 507ntail greater toxicity. Thus, the challenge of trans-
lantation in AA is to achieve high engraftment rates,
hereas minimizing transplant-related morbidity and
ortality. This has implications for every aspect of
ransplantation, as discussed in the next sections.
onditioning Regimen
If graft failure depends on residual host immune
ells, intensifying the conditioning regimen should be
eneﬁcial. This was initially accomplished through the
ddition of radiation to conditioning. Indeed, radiation-
ontaining conditioning regimens resulted in lower
ates of graft failure, as documented in several series
19], including European Bone Marrow Transplant
egistry (EBMT) and International Bone Marrow
ransplant Registry (IBMT) studies [18,20,21]. Un-
ortunately, radiation is also associated with signiﬁcant
arly and late toxicity, including secondary malignan-
ies [22]. In fact, in the above studies, there was no
urvival advantage to total-body irradiation (TBI) or
otal lymphoid irradiation regimens; the advantage of
ower graft failure rates was negated by a higher inci-
ence of acute GVHD (aGVHD) and pulmonary toxic-
ty [20,21].
This deadlock was broken with the introduction of
ntithymocyte globulin (ATG) in the conditioning
egimen, pioneered by Smith and colleagues in Boston
23], and by the Seattle group (who initially studied
he combination of cyclophosphamide and ATG as
art of the conditioning regimen for third trans-
lants in patients with GF [24], and applied this
xperience to second transplants [25], and thereafter
o ﬁrst transplants [26]). In a recent analysis of 81
atients receiving an MRD graft with Cy  ATG
onditioning, excellent outcomes were reported, with
ates of engraftment of 96%, aGVHD (grade II-IV) of
4%, and chronic GVHD (cGVHD) of 26% [27].
ith median follow-up of almost a decade, 15-year
verall survival (OS) was 88%. The beneﬁt of Cy 
TG conditioning over Cy  radiation was further
onﬁrmed by a French retrospective study of 133
atients transplanted from matched siblings [28]. In this
nalysis, use of thoraco abdominal irradiation in com-
ination with cyclophosphamide was associated with
able 3. Results of Selected Studies of Immunosuppressive Therapy for
Study N* Median Age (Range)
rickhofen et al [71,75]† 43 32 (7-80) ALG
41 32 (2-67) ALG
osenfeld et al [74] 122 35 ATG
ojima et al [104]† 110 9 (1-18) ATG
LG indicates antilymphocyte globulin; MP, methylprednisolone;
Number of patients.
Study included patients with nonsevere aplastic anemia.
 granulocyte colony-stimulating factor.igher GVHD rates (both aGVHD and cGVHD) and mower OS, compared to use of Cy ATG (55% versus
5%). In this series, as in the one above, patients
onditioned with Cy  ATG had excellent long-term
urvival. Therefore, Cy (200 mg/m2 divided in 4 daily
oses)  ATG (90 mg/kg divided in 3 daily doses) is
he current standard for MRD transplant condition-
ng.
The beneﬁt of ATG also extends to alternative
onor transplantation. In this setting, the rates of GF
re higher, likely reﬂecting a host-versus-graft im-
une attack that is increased by the greater antigenic
isparity (presumably at minor histocompatibility
oci). This made it more difﬁcult to eliminate radia-
ion from the conditioning regimen [29]. Kojima and
olleagues [30] conducted a retrospective study of 154
apanese patients receiving alternative donor trans-
lants for severe AA. They showed that survival was
uperior when ATG was used in the conditioning
egimen (5-year OS of 61%-75% versus 24%-53%,
hich was signiﬁcant in multivariable analysis). In a
ulticenter prospective study of 87 patients receiving
rafts from alternative donors (62 matched unrelated
onors (MUD) and 25 mismatched unrelated donors
MMUD)), Deeg and colleagues [31] attempted to
eﬁne the optimal TBI dose (in combination with Cy
nd ATG) in this setting. GF rates remained accept-
bly low with a radiation dose as low as 200 cGy (1%
or MUD and 12% for MMUD), and survival was not
ompromised by decreasing the total body irradiation
TBI) dose. In fact, for MUD allografts, survival was
ighest in the 200 cGy cohort (although this did not
chieve statistical signiﬁcance). This conclusion is
upported by the study of Kojima et al [30] cited
bove, which demonstrated excellent survival (90%)
or the small group of patients who received 500 cGy
r less of radiation in addition to Cy and ATG. Based
n those data, the combination of Cy 200 mg/m2,
TG 90 mg/kg, and TBI 200 cGy is a reasonable
hoice of conditioning regimen for alternative donor
ransplants. By extension, this could also be a reason-
ble conditioning regimen for heavily pretransfused
atients undergoing MRD transplant. A high number
f pretransplant transfusions has been associated with
n increased incidence of GF [20], and those patients
Anemia
tment Response Relapse Survival
 CSA 70% at 4 months 45% 11 y OS  58%
41% at 4 months 30% 11 y OS  54%
 CSA 60% at 3 mths 35% 7 y OS  55%
A  DAN‡ 68% at 6 months 22% 3 y OS  88%
yclosporine; DAN, danazol; OS, overall survival.Aplastic
Trea
 MP
 MP
 MP
 CS
CSA, cay therefore be more akin to those receiving an
a
b
a
m
i
e
t
c
A
T
i
a
e
i
c
T
i
t
h
a
y
v
[
7
l
2
i
o
l
a
n
t
3
r
c
g
7
(
c
w
t
u
i
i
p
c
p
I
O
p
z
p
1
n
i
r
w
s
t
z
T
u
G
c
o
1
m
f
h
G
i
w
G
I
a
w
f
t
T
t
c
a
l
s
o
t
l
M
d
p
(
5
2
t
r
l
b
s
i
i
t
i
r
T
T
P. Armand and J. H. Antin508lternative donor transplant (although this is certainly
eyond the scope of available data).
Once again, the success of ATG in conditioning
plastic patients for HSCT is consistent with the im-
une hypothesis of AA. The antihematopoietic activ-
ty in AA appears to be largely T cell dependent, as
videnced by laboratory and clinical data [3]. Indeed,
he standard of care for IST is the combination of a
alcineurin inhibitor (cyclosporine or tacrolimus) and
TG [32], which are both T cell-targeting drugs.
hus, speciﬁcally targeting the T cell population dur-
ng transplant conditioning should maximize efﬁcacy
nd minimize toxicity, compared to the broadly my-
lotoxic effects of radiation. It is therefore not surpris-
ng that the newest agents used in transplantation
onditioning, ﬂudarabine and alemtuzumab, are also
cell targeting agents.
Accumulating evidence with ﬂudarabine-contain-
ng conditioning regimens is encouraging and consis-
ent across studies. Two multicenter EBMT studies
ave examined ﬂudarabine’s role in both MRD and
lternative donor transplants. In a retrospective anal-
sis of 45 adult patients receiving MRD grafts with
arious ﬂudarabine-containing conditioning regimens
33], OS (with median follow-up of 21 months) was
7% for the patients receiving ﬂudarabine, ATG, and
ow-dose (200 mg/kg) cyclophosphamide (versus
4% for other regimens). Those results are not easy to
nterpret given the high patient and treatment heter-
geneity (as this study included frontline and second-
ine transplants, marrow and peripheral blood grafts,
nd various GVHD prophylaxis regimens); fortu-
ately, ongoing prospective studies should consolidate
hose promising results. A prospective EBMT study of
8 patients receiving alternative donor grafts with a
adiation-free conditioning regimen of ﬂudarabine,
yclophosphamide, and ATG showed reasonable en-
raftment (82% overall, 68% in adult patients), and a
3% 2-year OS (with short follow-up) [34]. aGVHD
grade II-IV) occurred in only 11% of patients, and
GVHD in 27%. Those early results compare favorably
ith those obtained with radiation-containing condi-
ioning, are consistent with other reports in related and
nrelated transplants [35-39], and warrant further stud-
es to deﬁne the optimal ﬂudarabine-based regimen.
The experience with alemtuzumab is more prelim-
nary. A British study described the outcome of 33
atients receiving a MRD graft conditioned with cy-
lophosphamide and alemtuzumab [40]. Seventy-six
ercent of patients engrafted, 14% developed grade
I-IV aGVHD, and 4% developed cGVHD; 5-year
S was 81%. The same group transplanted 7 young
atients with a MUD graft conditioned with alemtu-
umab, ﬂudarabine, and cyclophosphamide [41]. All
atients engrafted, with no grade III-IV aGVHD and
7% cGVHD. OS in this study was 71%. It should be
oted that 4 of the 7 patients had congenital AA, includ- fng 3 with Fanconi anemia (who, as discussed below,
equire a different conditioning regimen from patients
ith acquired AA). Another study from Poland de-
cribed 100% survival in 5 patients with severe AA
ransplanted from matched siblings after alemtu-
umab, ﬂudarabine, and melphalan conditioning [42].
hose results are promising and deserve further eval-
ation.
VHD Prophylaxis
Initially, GVHD prophylaxis after transplantation
onsisted of methotrexate (Mtx) alone. The usefulness
f cyclosporine (CSA) was ﬁrst suggested in the early
980s by a retrospective study of 37 patients receiving
ostlyCy-conditionedMRDtransplants [43].Twenty-
our patients received CSA, and were compared to 14
istoric controls who had received Mtx alone for
VHD prophylaxis. Engraftment rates were superior
n the CSA-treated patients (92% versus 74%). OS
as also higher (73% versus 56%), even though
VHD was actually more common in the CSA group.
nterestingly, 3 patients in this study lost their graft
fter initially successful engraftment, concomitantly
ith the withdrawal of CSA. This pattern of late graft
ailure has been subsequently reported in other pa-
ients [44,45], in association with mixed chimerism.
his suggests that the beneﬁt of CSA in AA transplan-
ation may be not so much in improving GVHD
ontrol but in suppressing the host immune system
nd thereby preventing early graft rejection. This il-
ustrates once again the importance of T cell suppres-
ion in the treatment of AA.
The beneﬁt of CSA for survival was conﬁrmed in
ther retrospective studies [20,46], and in an inﬂuen-
ial prospective trial conducted by Storb and col-
eagues [47]. In this trial, 46 patients receiving an
RD transplant after Cy-only conditioning were ran-
omized to Mtx with or without CSA for GVHD
rophylaxis. Patients receiving combined therapy
CSAMtx) had a lower risk of aGVHD (18% versus
3%), similar engraftment rates, and an improved
-year OS (82% versus 60%), which remained statis-
ically signiﬁcant in multivariate analysis. Another
andomized trial conducted by Locatelli and col-
eagues [48] showed a similar survival beneﬁt to com-
ined CSA  Mtx treatment.
Since that time, no other regimen has shown clear
uperiority over the combination of calcineurin inhib-
tor (CSA or tacrolimus) and Mtx. There is only lim-
ted experience with T cell depletion in transplanta-
ion for AA. However, most of the data point to an
ncreased risk of GF [20,49]; hence, this cannot be
ecommended outside the context of a clinical trial.
here is also no compelling physiologic reason why
cell depletion should be useful in AA, where theundamental goal is suppression of recipient T cell
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Allogeneic Stem Cell Transplantation 509unction. Whether GVHD prophylaxis regimens us-
ng combinations of other T cell targeting agents,
uch as rapamycin or mycophenolate mofetil (MMF),
an improve on the results with CSA  Mtx, remains
o be determined. There are isolated reports that
SA  MMF prophylaxis is an acceptable regimen
37,50], but the experience is as of yet too limited to
eliably compare this regimen to CSA  Mtx.
ource of Stem Cells
Up to now, most transplantation studies in AA
ave used unmanipulated bone marrow as the stem
ell source. In recent years, there has been an explo-
ive increase in the use of peripheral blood stem cells
PBSC) in HSCT for other indications. The success-
ul use of PBSC transplants in AA has been reported
51,52]. However, a retrospective EBMT study con-
luded that use of PBSC, despite providing faster
ngraftment, was associated with an increased inci-
ence of cGVHD and a signiﬁcantly lower 2-year
urvival compared to marrow grafts (67% versus 80%)
53]. This is reminiscent of the results using posttrans-
lant buffy coat infusion in Seattle: even though this
rocedure increased engraftment rates, it was associ-
ted with a higher incidence of chronic GVHD and
as ultimately abandoned [54]. At present, it therefore
eems wise to use bone marrow grafts, at least outside
f a clinical trial.
Umbilical cord blood (UCB) is also increasingly
eing used as a source of stem cells, as this allows the
ransplantation of patients without an HLA-matched
onor. A group in China treated 9 young adults suf-
ering from severe AA with umbilical transplants using
yclophosphamide and antilymphocyte globulin con-
itioning [55]. Seven of the 9 patients had some level
f engraftment, evidenced by the presence of stable
ixed chimerism. After a median follow-up of 32
onths, survival was nearly 80%. Successful complete
himerism was reported in a pediatric patient after an
mbilical cord graft [56]; stable engraftment was also
chieved after UCB grafts in children with congenital
A in two other reports [57,58]. Umbilical cord trans-
lants therefore appear to be an option for patients
ith AA who lack a suitable donor, but more experi-
nce is needed to determine the long-term outcome of
his approach.
ELECTION OF PATIENTS FOR UPFRONT
RANSPLANTATION
he Challenge
Under the best circumstances, allogeneic trans-
lantation can result in excellent outcomes. Long-
erm follow-up of young patients transplanted from
atched related donors in several studies have docu-
ented a 10-year survival in excess of 80%, with most aurvivors having a normal performance status [27,59-
1]. This seems to apply irrespective of the cause of
A (as long as it is acquired AA). Patients with a drug
r viral trigger, or patients with pregnancy-associated
A, are usually included in studies of acquired AA, and
ith some exceptions of unclear signiﬁcance [62,63],
heir outcome appears to be similar to that of patients
ith idiopathic acquired AA [6,60]. HSCT is also
otentially curative for patients whose AA is associated
ith PNH, as ﬁrst demonstrated in the 1970s [64,65]
nd subsequently conﬁrmed in many small studies
66-68]; again, there is no evidence that those patients
o worse after HSCT than their counterparts with AA
lone.
Those numbers, however, do not apply to older
atients or those without an HLA-matched sibling,
ho do signiﬁcantly worse after transplantation [7].
ther adverse prognostic factors that have consis-
ently emerged from multivariate analyses are omis-
ion of CSA from the GVHD prophylaxis regimen,
arlier year of transplantation, longer time from diag-
osis to transplantation, and gender mismatching
6,17,30,49,69,70]. Moreover, HSCT carries risks
hat, though not fatal, can nonetheless signiﬁcantly
ffect quality of life. These include aGVHD and
GVHD (the latter affecting 20%-50% of long-term
urvivors [59,60]). Transplant survivors are also at
ncreased risk of growth abnormalities (for children),
nfertility, cataracts, hypothyroidism [61], and second-
ry solid tumors (with a 20-year risk around 2%, or
igher in patients who have received radiation) [22].
This must be weighed against the risks and bene-
ts of IST. The standard of care for IST is currently
he combination of CSA (or tacrolimus) and ATG
used here interchangeably with antilymphocyte glob-
lin [ALG]), based largely on the results of a German
andomized trial [71] (and the disappointing results of
sing instead high-dose cyclophosphamide with autol-
gous recovery [72,73]). In Europe and the United
tates, this regimen has a response rate of 60%-65%,
nd is associated with long-term (7 to 11 years) OS
round 55% [74,75]. Here, too, there is some prog-
ostic heterogeneity, with younger patients [76] and
hose with less severe disease [76-78] having a superior
utcome (although the prognostic role of disease se-
erity has been questioned in other series [6]). Natu-
ally, IST also carries signiﬁcant risks. The rate of
elapse is 35%-45%; and whereas around 2/3 of pa-
ients who relapse can respond to a second course of
ST [79], this contributes to morbidity and mortality.
ore ominously, patients with AA treated with IST
ave a signiﬁcant risk of developing late clonal abnor-
alities, including PNH, myelodysplastic syndrome
MDS), and acute myelogenous leukemia (AML). The
atter two complications are the major cause of pre-
ature death for patients who survive beyond 3 yearsfter IST. In large series of patients treated with IST,
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P. Armand and J. H. Antin510he rate of development of PNH was 15%-20%, and
f MDS/AML was 10%-20% [3,80]. Finally, patients
reated with IST also are at increased risk for second-
ry solid tumors, with an incidence around 2%, sim-
lar to that after HSCT [81].
The foregoing highlights the challenge of choos-
ng between IST and HSCT as frontline treatment for
given patient. The two modalities have very different
oxicity proﬁles, and different prognostic factors. This
s further complicated by the issue of historic trends.
ndeed, the outcome of AA treatment since the 1970s
as improved dramatically. This has been particularly
rue in the ﬁeld of transplantation, with many large
ulticenter retrospective series documenting an abso-
ute increase in OS over the last 20 years approaching
0% (see Figure 1) [6,17,18,46,82,83]; this trend has
ontinued even after 1991 [84]. Many of the respon-
ible factors have been previously discussed. Another
actor that bears mention is improvement in support-
ve care, especially the change in transfusion practice.
s mentioned above, heavily pretransfused patients
ave a worse outcome [20,21,30,82], presumably by
llo-immunization in patients who already have anti-
ematopoietic immune activity. Restricting pretrans-
lantation transfusions, using leuko-poor, irradiated
lood products, and using single-donor apheresis
latelet units, are likely responsible for part of the
mprovement in engraftment rates and survival. Better
nti-infectious agents, and the use of protective trans-
lant environments [85], also improve the survival of
eukopenic patients and thereby blunt the impact of
raft failure, as more patients can now survive to a
econd transplant.
Improvements in IST over time have also oc-
urred, although they are perhaps slightly less pro-
ounced. The trial that proved the value of today’s
tandard of care (CSA ATG) was published in 1991;
o regimen has since improved on those results, and
igure 1. Survival after matched sibling transplantation for severe
plastic anemia, by year of transplantation, from the European Bone
arrow Transplant registry (courtesy of Jakob Passweg, on behalfif the Working Party Aplastic Anemia of the EBMT).ven that regimen was not proved to signiﬁcantly
ncrease OS compared to ATG alone [75]. The dif-
ering time trends in the outcome of IST and HSCT
ake older studies or studies with a long time-span
ess useful when comparing the two modalities, and
linicians must therefore rely on recent studies that
annot capture long-term effects of therapy.
In the remainder of this review, we discuss several
linical scenarios, and in each case attempt to answer
he question of upfront treatment choice. We will
roceed in order of controversy, starting with situa-
ions where the answer is clear, and moving into areas
here no right answer exists and where we can only
ffer our perspective and practice, understanding that
t is impossible to answer the question with any degree
f certainty.
ongenital AA
The defects leading to inherited marrow failure
yndromes are not autoimmune, as they are in ac-
uired AA. Therefore, those patients will not respond
o IST, and HSCT is the only potentially curative
rocedure. For patients with Fanconi anemia (FA),
urvival following MRD HSCT may approach that of
atients transplanted for acquired AA (although pa-
ients with FA suffer from an increased incidence of
VHD and secondary malignancies [86]). Five-year
S of 60%-70% are typical, including in a large
BMT study [87]. As is the case for acquired AA,
urvival is worse after alternative donor HSCT [88].
The difﬁculty, then, is not so much in choosing
he right treatment for patients with congenital AA,
ut in recognizing which patients belong to this cat-
gory. In many cases, the diagnosis of an inherited
arrow failure syndrome is made in childhood, based
n the typical constellations of features that charac-
erize each of the disorders. However, some patients
o not develop marrow failure until adulthood; more-
ver, up to 1/3 of patients with FA (the most common
nherited marrow failure syndrome) do not display
bvious congenital anomalies [89]. The clinician ap-
roaching a patient with apparently acquired AA must
herefore diligently search for clues to a congenital
yndrome. In the case of FA, those include skin pig-
entation abnormalities (most classically café-au-lait
pots), hearing defects, macrocytosis, or solid tumors
ccurring at an unusually young age [90]; similarly,
ail malformations, a reticular rash, oral leukoplakia,
steoporosis, or pulmonary ﬁbrosis may suggest the
iagnosis of dyskeratosis congenital (DKC); whereas
xocrine pancreatic insufﬁciency may be a clue to the
chwachman-Blackfan-Diamond syndrome [2]. Be-
ause the telltale abnormalities may not be present in
he patient but in a family member, a thorough family
istory is essential. Once a diagnosis of congenital AA
s suspected, the appropriate diagnostic workup can be
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Allogeneic Stem Cell Transplantation 511ursued. For FA, chromosomal breakage testing can
e performed using mitomycin C or diepoxybutane.
f note, a minority of FA patients display somatic
osaicism, in which case diagnosis requires testing of
ultured skin ﬁbroblasts rather than hematopoietic
ells [91]. For the other inherited marrow failure syn-
romes, sequencing of the relevant genes must be
one.
The other important implication of a diagnosis of
ongenital AA relates to the choice of conditioning
egimen for transplantation. Patients with FA, who
arbor defects in DNA repair, are exquisitely sensitive
o DNA-damaging agents, so much so that standard
onditioning regimens are lethal. Dose reductions
usually 70%-90% for cyclophosphamide and 50%-
5% for radiation) are therefore essential. Fludarabine
ay also be useful in the conditioning regimen to
ake up for the dose reduction in Cy and TBI [92,93].
onsevere AA
Severe AA is deﬁned as marrow cellularity below
5% with at least 2 among: absolute neutrophil count
ANC) 0.5  109/L, platelets 20  109/L, and
bsolute reticulocyte count 20  109/L. Very severe
A is the same except that ANC must be below 0.2 
09/L [94]. Although there may be some prognostic
ifference between severe and very severe AA when
reated with IST, as discussed above (if not when
reated with HSCT [7,77]), it is clear that patients
ithout at least severe AA are best not transplanted,
nd treated instead with observation, androgens, or
ST. Their disease may remain mild or moderate and
ay even remit, and their survival (without HSCT) is
n excess of 90% [95].
yngeneic Transplantation
For the few patients lucky enough to have an avail-
ble identical twin donor, the outlook is extremely fa-
orable. Because the cure of AA does not require a
raft-versus-tumor effect, syngeneic transplants are
deal, as they minimize the risk of graft failure and
liminate that of GVHD. Hinterberger et al. [96]
nalyzed a cohort of 40 patients who received a syn-
eneic graft between 1964 and 1992, comparing those
ho received an unconditioned graft with those who
ere conditioned with cyclophosphamide-based regi-
ens. The use of conditioning signiﬁcantly improved
ngraftment rates (64% versus 30%), again consistent
ith the immune hypothesis of acquired AA; however,
here was no signiﬁcant difference in OS between the
atients who received conditioning prior to the ﬁrst
ransplantation attempt (with a 10-year OS of 70%)
nd those who did not (with a 10-year OS of 87%).
his implies a high salvage rate for patients with graft
ailure after an unconditioned syngeneic graft; as those
atients are spared both conditioning regimen toxicity vnd GVHD, they can more easily be supported until a
ubsequent conditioned transplant. In more recent
eries, syngeneic transplants are associated with a sur-
ival around 90% [6]. In this case, as with matched
ibling donor, radiation as part of the conditioning
egimen is not needed, and cyclophosphamide-alone
onditioning should be sufﬁcient.
atched Sibling Donor Transplantation
The current recommendation for patients with an
vailable matched sibling donor, as proposed by
acigalupo and colleagues [6], is to transplant patients
ounger than 40 and treat patients older than 40 with
ST (reserving HSCT for relapsing or refractory pa-
ients). This distinction is based on the favorable out-
omes with MRD HSCT in young patients, and the
dverse prognostic impact of advancing age. However,
here may be a rationale for using an older age cutoff
n this case. As discussed above, the outcomes of MRD
SCT have improved markedly in the last 20 years.
he benchmarks for HSCT outcomes should there-
ore be based on patients transplanted after 1990. In a
etrospective multicenter EBMT analysis, OS after
SCT for patients over 40 years of age transplanted
fter 1990 was 54% [6]. It must be noted that 14% of
atients in this study received a graft from alternative
onors. Moreover, not all patients were transplanted
pfront, and the outcome of HSCT is worse for pa-
ients who have previously received IST [18,63].
herefore, the true OS after MRD HSCT in this age
roup is likely higher than 54%.
The most directly comparable numbers using IST
ome from another EBMT analysis of older patients
76]. In this study, the 5-year OS for patients aged
0-59 treated after 1990 was 60%. Although the 2
umbers (54% and 60%) are very comparable, several
ssues should be kept in mind. First, HSCT has the
mportant advantage of avoiding the risk of late clonal
iseases (12% at 10 years in the above IST study).
ndeed, survival curves for patients treated with IST
o not reach a plateau as clearly as the corresponding
urves after HSCT, and there appears to be up to a
0% absolute decrease in survival between 5 and 10
ears after IST in studies with long-term follow-up
75,77]. Second, patients in their 50s are close to the
utoff age for transplantation. If they are treated with
n attempt at IST and relapse after a few years, they
ay have lost the opportunity for transplantation.
Given this, it may be reasonable to consider trans-
lantation for ﬁrst-line therapy in patients with severe
A up to the age of 55 or so when a matched sibling
onor is available. For patients between the ages of 40
nd 55, for whom the true difference in outcome
etween HSCT and IST is likely small, other prog-
ostic considerations should weigh in. Patients with
ery severe AA (ANC below 0.2  109/L), as previ-
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P. Armand and J. H. Antin512usly mentioned, appear to do worse than those with
evere AA (ANC between 0.2 and 0.5  109/L) when
reated with IST, but not when transplanted [7,76-
8,90]. Therefore, transplantation may be preferable
or those patients. In contrast, patients with associated
NH clones (even if only apparent on ﬂow cyto-
etric studies) may do better after IST than pa-
ients with AA alone [97,98]. IST may therefore be
he treatment of choice in this case. The unavailabil-
ty of a gender-matched donor may also militate in
avor of IST [70].
UD Transplantation
The current recommendation is to treat all pa-
ients without an available MRD with at least 2 at-
empts at IST prior to resorting to transplantation [6],
ased on the poorer results of MUD compared to
RD HSCT. Here also, our own perspective is more
iased in favor of transplantation. Indeed, transplan-
ation from alternative donors has beneﬁted from the
ame improvements over time as has transplantation
rom matched siblings, even though the improvement
n survival has been less dramatic. In a recent IBMT
etrospective study of patients transplanted between
988 and 1994, Passweg and colleagues [99] reported
5-year OS after MUD transplantation of 39%, with
ge over 21 years and poor performance status being
dverse risk factors for survival. However, more recent
rospective experiences have demonstrated superior
esults. An EBMT trial of 38 children and young
dults using ﬂudarabine  Cy  ATG conditioning
eported a 2-year OS of 74%, and 84% for patients
nder the age of 18 [34]. A recent comparison of
lternative and matched related donors for pediatric
ransplants found no difference in OS [100]. More-
ver, in the study of Deeg and colleagues [31] on TBI
eescalation cited above, which was based on patients
ransplanted between 1994 and 2004, the survival after
UD HSCT was 61% (66% for those patients con-
itioned with 200 cGy TBI), and 73% for patients
nder the age of 21. The difference in outcomes
etween the study of Passweg and colleagues and the
ther cited studies might be explained by the quality
f HLA typing. In Passweg et al’s study, most patients
ere typed at low resolution, whereas in the others
olecular typing was performed. This is signiﬁcant
ecause the outcome with mismatched unrelated do-
ors is worse than that with matched unrelated donors
30,31,49]. Transplantation using molecularly matched
nrelated donors and modern conditioning regimens
ay therefore yield survivals of 60%-80% in young
atients. The beneﬁt of allele-level HLA matching has
ecently been conﬁrmed in a retrospective French
tudy, in which young patients with fully HLA-
atched unrelated donors had a 5-year survival of
8% [101]. It must also be remembered that, because pf the historically poor outcomes with alternative do-
or transplants, patients receiving MUD transplants
n clinical trials are patients who have previously failed
t least one, and usually more courses of IST. In the
tudy of Deeg et al [31], for example, patients had
eceived a median of 3 courses of IST. The literature
n MRD transplants has repeatedly demonstrated that
onger time to HSCT and prior immunosuppression
re adverse risk factors [21,30,49,63,102]. Therefore,
he 60%-80% survival mentioned above could even
nderestimate the true survival of young patients trans-
lanted with allele-level MUD allografts as front-line
herapy.
Based on this, HSCT could be considered as ﬁrst-
ine treatment for patients with severe AA under 21
ears old (acknowledging the necessarily arbitrary na-
ure of such a cutoff) for whom a molecularly matched
nrelated donor is available. For older patients, or for
atients without an allele-level MUD, IST is likely
till the appropriate choice for frontline therapy.
he Patient without an Available Matched
ibling or Unrelated Donor
As discussed above, outcomes after mismatched
ransplantation are poor, and the experience with
mbilical cord grafts is still too sparse to justify its
pfront use. Therefore, such patients should receive
n attempt at IST (which can be repeated in case of
ailure or relapse). Only once IST options are ex-
austed can the risks of mismatched or UCB grafts
e justiﬁed.
ONCLUSION
The last 30 years have brought great progress both
n our understanding of AA and in its treatment, so
uch so that the majority of patients can be cured
ith current therapies. Nonetheless, choosing the
ight treatment for an individual patient is a challeng-
ng task that begins with ruling out the presence of an
nherited marrow failure syndrome. For patients with
cquired severe AA, the choice of treatment depends
rincipally on the patient’s age and the availability of
matched donor. Assuming transplantation eligibility,
e would consider this modality as front-line therapy
or any patient with an available syngeneic donor, for
atients up to the age of 55 or so with a matched
ibling donor, and for patients up to the age of 21 or
o with an allele-level HLA-matched unrelated do-
or. For all other patients, we would recommend
ST as initial treatment. If history is a guide, the
oming years will bring new developments in this
eld, requiring further reexamination of this ques-
ion, and will continue to improve the prognosis of
atients with this fascinating disease.
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